HSBC Downgrades AstraZeneca to 'Hold' on Wainua Trial Setback, Slashes Price Target

HSBC downgraded AstraZeneca (NASDAQ: AZN) to Hold from a previous Buy rating, citing a more difficult outlook following a significant clinical trial failure. The bank also slashed its price target on the pharmaceutical giant's London-listed shares to £13,750 from £16,500, prompting a dip in the company's stock.

Rationale for the Downgrade

The move was triggered by AstraZeneca's Wainua drug failing to meet its primary endpoint in a Phase 3 study known as the CARDIO-TTR trial. In a note to clients, HSBC analyst Rajesh Kumar stated that this "setback impairs our bull case."

HSBC had previously viewed the trial's success as a cornerstone of its positive outlook, representing a potential market opportunity of more than $5 billion. With the trial's failure, the bank has lost conviction in its previously bullish stance on the company's prospects.

A More Volatile Path Ahead

HSBC outlined several reasons for its increased caution on AstraZeneca's future performance. The bank noted that while a path to over $80 billion in peak revenues by 2030 may still exist, it now hinges on catalysts that are more volatile and unlikely to produce results before 2027.

Ad

Furthermore, the analyst expressed discomfort with the upcoming readouts for the SERENA-4 and AVANZAR trials, which are expected in the second half of 2026. Kumar warned that a sequence of trial failures could tarnish the market's perception of AstraZeneca's market-leading R&D platform, potentially limiting the stock's ability to re-rate higher.

Market Impact

Following the downgrade, AstraZeneca's shares fell 1.3% in London trading. The company's U.S.-listed shares also declined, shedding 1.5% in pre-market activity.

HSBC concluded that the risk-reward balance for the stock is no longer attractive. The bank sees the remaining catalyst path for 2026 as being "skewed to downside risks," solidifying its decision to move to a Hold rating.